Study examines canine plasma xenotransfusion in 14 cats: full analysis
A newly listed study in the Journal of Veterinary Emergency and Critical Care examines 14 feline cases of canine plasma xenotransfusion across multiple centers from 2022 to 2024, offering one of the first focused looks at this specific practice. From the abstract, the authors assessed indications, transfusion protocols, reactions, and outcomes, and concluded that canine plasma xenotransfusion can serve as a life-saving option for feline coagulopathies and colloidal support when feline plasma is unavailable, though more work is needed to clarify safety. The article was posted in the journal’s recent-articles feed on April 30, 2026. (vetlit.org)
That matters because xenotransfusion in cats is not new, but the evidence base has centered mostly on canine red blood cells or whole blood, not plasma. Earlier reviews describe canine-to-feline xenotransfusion as an emergency workaround when compatible feline blood cannot be obtained. Those reports suggest cats generally do not have naturally occurring antibodies against canine red blood cells before a first transfusion, but they can develop antibodies rapidly afterward, with delayed hemolytic reactions often emerging within days and repeat canine red cell transfusion becoming high risk. (pmc.ncbi.nlm.nih.gov)
More recent feline studies have reinforced both the utility and the limits of xenotransfusion. A 49-case review found canine blood xenotransfusion could stabilize cats initially, but delayed hemolytic reactions were common. A later retrospective comparison of canine xenotransfusion versus type-matched feline allotransfusion added to the evidence that clinicians still turn to xenotransfusion under practical constraints, including limited access to feline products and, in some settings, cost considerations. (pubmed.ncbi.nlm.nih.gov)
Against that backdrop, the new plasma-focused report fills an important gap. The abstract indicates the 14 cats were treated for coagulopathies and for colloidal support, which suggests the product was being used not simply as a substitute transfusion, but for distinct hemostatic and oncotic goals. That lines up with adjacent literature showing how clinicians have been experimenting with other canine-derived products in cats when feline-specific options are lacking. In 2025, for example, a small retrospective Frontiers case series described canine serum albumin use in five critically ill cats and suggested it may provide oncotic and hemodynamic support, while still documenting possible transfusion-related complications, including one case attributed to circulatory overload. A separate case report described canine lyophilized platelets being used for hemostasis in a cat with postoperative hemorrhage. (frontiersin.org)
Direct outside commentary on this new paper was limited in the sources I could verify, but the broader expert literature has been consistent on the core message: xenotransfusion can be justified as a rescue strategy, not a routine substitute for feline products. Review articles and transfusion guidance emphasize that species-matched feline blood products remain the standard when available, while canine-derived products are considered because feline donors and feline blood banks remain harder to access in urgent settings. Merck’s veterinary reference also reflects the broader transfusion-medicine reality that blood typing, donor screening, and product selection remain central to safety in both dogs and cats. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this study is useful less as a practice-changing mandate than as decision support for difficult cases. Emergency hospitals, specialty centers, and overnight teams may occasionally face a cat with coagulopathy or a need for plasma-based colloidal support when feline plasma is simply not on hand. In that setting, even retrospective multicenter data can help frame risk-benefit discussions, monitoring plans, and informed consent with the pet parent. The study also highlights a larger operational issue in companion animal medicine: feline transfusion support still lags behind canine infrastructure in many markets, pushing clinicians toward improvised but potentially life-saving alternatives. (vetlit.org)
The unanswered questions are just as important. The abstract does not, at least from the publicly available summary, resolve which protocols were safest, how often reactions occurred, whether certain indications carried better outcomes, or how product choice and dosing varied by center. Those details will matter if hospitals are going to translate the findings into protocols. Prospective studies, standardized reaction reporting, and more published guidance from transfusion specialists would all help determine whether canine plasma xenotransfusion should remain a rare contingency tool or become a more formal part of feline critical care planning. (vetlit.org)
What to watch: The next step is the full paper itself, followed by conference discussion, specialist commentary, and any larger prospective work that clarifies candidate selection, dosing, monitoring, and short-term versus delayed adverse events. (vetlit.org)